Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Irx Therapeutics has raised $25 million through a series A preferred stock offering. To date, the company has raised more than $65 million in private financing.
Subscribe to our email newsletter
The new funding will be used to further develop its cancer and viral disease product platform, including IRX-2 (citoplurikin), the company’s lead candidate for cancer treatment.
The company is developing an approach that seeks to stimulate a coordinated cellular immune response that can enable a patient’s own immune system to fight disease. The overall goal of these programs is to increase survival and improve quality of life for patients.
John Hadden II, president and CEO of Irx Therapeutics, said: “With this new funding, we are well positioned to continue the development of our lead product, citoplurikin, and build upon previous clinical trial success.”